Table 1 Descriptive statistics for fully vaccinated individuals.

From: Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine

 

30 DAY POST-VACCINATION BINARY OUTCOME

60 DAY POST-VACCINATION BINARY OUTCOME

90-DAY POST-VACCINATION BINARY OUTCOME

POST-VACCINATION TIME-TO-EVENT

BNT162b2

mRNA-1273

BNT162b2

mRNA-1273

BNT162b2

mRNA-1273

BNT162b2

mRNA-1273

N

1,380,571

1,058,703

577,390

576,021

218,727

168,203

2,364,605

1,598,450

Age, mean (SD)

56.17 (17.30)

59.82 (17.42)

61.14 (18.25)

62.62 (17.67)

57.16 (19.30)

56.14 (18.34)

50.67 (17.46)

55.39 (17.84)

Elixhauser readmission score, mean (SD)

5.95 (11.64)

6.87 (12.22)

7.76 (13.66)

7.63 (12.86)

7.68 (14.59)

6.05 (11.76)

4.65 (10.16)

5.83 (11.32)

Transferred from nursing facility/ SNF (%)

2,368 (0.2)

719 (0.1)

2,236 (0.4)

609 (0.1)

1873 (0.9)

420 (0.2)

2465 (0.1)

832 (0.1)

Sex

 Female (%)

780,162 (56.5)

608,628 (57.5)

354,134 (61.3)

344,902 (59.9)

143,348 (65.5)

105,587 (62.8)

1,264,075 (53.5)

874,407 (54.7)

 Male (%)

600,409 (43.5)

450,075 (42.5)

223,256 (38.7)

231,119 (40.1)

75,379 (34.5)

62,616 (37.2)

1,100,530 (46.5)

724,043 (45.3)

Residence by region (%)

 Midwest

439,164 (31.8)

304,757 (28.8)

185,910 (32.2)

164,256 (28.5)

67,205 (30.7)

39,086 (23.2)

752,567 (31.8)

467,702 (29.3)

 Northeast

190,544 (13.8)

155,541 (14.7)

77,097 (13.4)

80,167 (13.9)

33,699 (15.4)

32,208 (19.1)

335,877 (14.2)

228,427 (14.3)

 South

395,294 (28.6)

323,742 (30.6)

141,732 (24.5)

172,565 (30.0)

58,464 (26.7)

64,696 (38.5)

672,676 (28.4)

481,238 (30.1)

 West

355,569 (25.8)

274,663 (25.9)

172,651 (29.9)

159,033 (27.6)

59,359 (27.1)

32,213 (19.2)

60,3485 (25.5)

421,083 (26.3)

 First dose administered before Feb 1, 2021* (%)

317,863 (23.0)

359,372 (33.9)

317,863 (55.1)

359,372 (62.4)

86,899 (39.7)

82,298 (48.9)

317,863 (13.4)

359,372 (22.5)

 SES index, mean (SD)

53.36 (2.85)

52.85 (3.13)

53.12 (2.80)

52.68 (3.15)

52.91 (2.80)

52.81 (3.34)

53.70 (2.90)

53.08 (3.12)

Study-related outcomes

 Infection (%)

3766 (0.3)

1949 (0.2)

3376 (0.6)

1724 (0.3)

2514 (1.1)

861 (0.5)

5758 (0.2)

3090 (0.2)

 Hospitalization/ ICU/ deceased/ transferred to hospice (%)

72 (0.0)

42 (0.0)

82 (0.0)

49 (0.0)

55 (0.0)

23 (0.0)

129 (0.0)

85 (0.0)

 ICU/ deceased/ transferred to hospice (%)

32 (0.0)

14 (0.0)

36 (0.0)

21 (0.0)

26 (0.0)

8 (0.0)

57 (0.0)

40 (0.0)

 Hospitalization (%)

58 (0.0)

35 (0.0)

67 (0.0)

39 (0.0)

46 (0.0)

21 (0.0)

105 (0.0)

69 (0.0)

 ICU (%)

28 (0.0)

14 (0.0)

30 (0.0)

21 (0.0)

20 (0.0)

7 (0.0)

47 (0.0)

38 (0.0)

 Deceased/ transferred to hospice (%)

9 (0.0)

2 (0.0)

12 (0.0)

1 (0.0)

10 (0.0)

1 (0.0)

21 (0.0)

7 (0.0)

  1. Descriptive statistics for baseline characteristics (demographics, socioeconomic, comorbidities, negative controls, study outcomes, and other prognostic factors) among fully vaccinated individuals by BNT162b2 and mRNA-1273. Analytical datasets are separated into those fully vaccinated by May 1, 2021, April 1, 2021, and March 2, 2021, ensuring each patient had at least 30, 60, and 90 days of post-vaccination follow-up to experience events, respectively. For time-to-event outcomes we consider individuals vaccinated by June 1, 2021.
  2. Note: A more comprehensive descriptive table (Table S1) is provided in the supplementary section.
  3. *For the 90-day outcome the date was adjusted to “First dose administered before January 10, 2021.”
Back to article page